Toxic animal models

Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics

Volumn , Issue , 2005, Pages 196-221

  Przedborski, Serge ^a   Tieu, Kim ^b  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 17644422707     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544873.017     Document Type: Chapter

References (265)

1. Abe, K., Taguchi, K., Wasai, T. et al. (2001). Stereoselective effect of (R)- and (S)-1-methyl-1, 2, 3, 4-tetrahydroisoquinolines on a mouse model of Parkinson's disease. Brain Res. Bull., 56, 55-60.
2. Agid, Y., Javoy, F., Glowinski, J., Bouvet, D. & Sotelo, C. (1973). Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. Brain Res., 58, 291-301.
3. Albers, D. S. & Sonsalla, P. K. (1995). Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther., 275, 1104-14.
4. Albin, R. L. & Greenamyre, J. T. (1992). Alternative excitotoxic hypotheses. Neurology, 42, 733-8.
5. Ali, S. F., Newport, G. D., Holson, R. R., Slikker, W., Jr. & Bowyer, J. F. (1994). Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res., 658, 33-8.
6. Alston, T. A., Mela, L. & Bright, H. J. (1977). 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl Acad. Sci., USA, 74, 3767-71.
7. Antkiewicz-Michaluk, L., Romanska, I., Papla, I. et al. (2000). Neurochemical changes induced by acute and chronic administration of 1, 2, 3, 4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience, 96, 59-64.
8. Ara, J., Przedborski, S., Naini, A. B. et al. (1998). Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Proc. Natl Acad. Sci., USA, 95, 7659-63.
9. Araki, M., McGeer, P. L. & McGeer, E. G. (1985). Differential effect of kainic acid on somatostatin, GABAergic and cholinergic neurons in the rat striatum. Neurosci. Lett., 53, 197-202.
10. Axt, K. J., Mamounas, L. A. & Molliver, M. E. (1994). Structural features of amphetamine neurotoxicity in the brain. In Amphetamine and its Analogs. Psychopharmacology, Toxicology, and Abuse, ed. A. K. Cho & D. S. Segal, pp. 315-367. NewYork: Academic Press.
11. Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M. & Kopin, I. J. (1986). Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1- methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine(MPTP). Life Sci., 39, 7-16.
12. Beal, M. F., Kowall, N.W., Ellison, D.W., Mazurek, M. F., Swartz, K. J. & Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 321, 168-71.
13. Beal, M.F., Ferrante, R. J., Swartz, K. J. & Kowall, N.W. (1991). Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci, 11, 1649-59.
14. Beal, M.F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B. & Hyman, B. T. (1993a). Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem., 61, 1147-50.
15. Beal, M. F., Brouillet, E., Jenkins, B. G. et al. (1993b). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci., 13, 4181-92.
16. Ben Ari, Y. & Cossart, R. (2000). Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci., 23, 580-7.
17. Bergman, H., Wichmann, T. & DeLong, M. R. (1990). Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-8.
18. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V. & Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat.Neurosci., 3, 1301-6.
19. Bezard, E., Imbert, C., Deloire, X., Bioulac, B. & Gross, C. E. (1997). A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res., 766, 107-12.
20. Bezard, E., Gross, C. E., Fournier, M.C., Dovero, S., Bloch, B. & Jaber, M. (1999). Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol., 155, 268-73.
21. Bjorklund, L. M., Sanchez-Pernaute, R., Chung, S. et al. (2002). Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl Acad. Sci., USA, 99, 2344-9.
22. Blum, D., Torch, S., Lambeng, N. et al. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol., 65, 135-72.
23. Boegman, R. J., Smith, Y. & Parent, A. (1987). Quinolinic acid does not spare striatal neuropeptide Y-immunoreactive neurons. Brain Res., 415, 178-82.
24. Borlongan, C. V., Koutouzis, T. K., Freeman, T. B., Cahill, D. W. & Sanberg, P. R. (1995). Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res., 697, 254-7.
25. Borlongan, C. V., Koutouzis, T. K. & Sanberg, P. R. (1997). 3- Nitropropionic acid animal model and Huntington's disease. Neurosci. Biobehav. Rev., 21, 289-93.
26. Bourn, W. M., Chin, L. & Picchioni, A. L. (1972). Enhancement of audiogenic seizureby 6-hydroxydopamine. J.Pharm.Pharmacol., 24, 913-14.
27. Breese, G. R., Baumeister, A. A., McCown, T. J., Emerick, S. G., Frye, G. D. & Mueller, R. A. (1984). Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacol. Biochem. Behav., 21, 459-61.
28. Breese, G. R., Criswell, H. E., Duncan, G. E. & Mueller, R. A. (1990). A dopamine deficiency model of Lesch-Nyhan disease - the neonatal-6-OHDA-lesioned rat. Brain Res. Bull., 25, 477-84.
29. Brooks, A. I., Chadwick, C. A., Gelbard, H. A., Cory-Slechta, D. A. & Federoff, H. J. (1999). Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res., 823, 1-10.
30. Brouillet, E., Jenkins, B. G., Hyman, B.T. et al. (1993). Age-dependent vulnerability of the striatum to the mitochondrial toxin 3- nitropropionic acid. J. Neurochem., 60, 356-9.
31. Brouillet, E., Hantraye, P., Ferrante, R. J. et al. (1995). Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl Acad. Sci., USA, 92, 7105-9.
32. Brouillet, E., Guyot, M. C., Mittoux, V. et al. (1998). Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J.Neurochem., 70, 794-805.
33. Brouillet, E., Conde, F., Beal, M. F. & Hantraye, P. (1999). Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol., 59, 427-68.
34. Burns, L. H., Pakzaban, P., Deacon, T. W. et al. (1995). Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience, 64, 1007-17.
35. Calabresi, P., Gubellini, P., Picconi, B. et al. (2001). Inhibition of mitochondrial complex II induces a long-termpotentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci., 21, 5110-20.
36. Callahan, B. T. & Ricaurte, G. A. (1998). Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. NeuroReport, 9, 2691-5.
37. Cao, L., Filipov, N. M. & Lawrence, D. A. (2002). Sympathetic nervous system plays a major role in acute cold/restraint stress inhibition of host resistance to Listeria monocytogenes. J. Neuroimmunol., 125, 94-102.
38. Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W. & Di Monte, D. (1991). Rapid ATP loss caused by 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine inmousebrain. J.Neurochem., 57, 348-51.
39. Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W. & Di Monte, D. (1992). MPTP-induced ATP loss in mouse brain. Ann. NY Acad. Sci., 648, 306-8.
40. Clausing, P. & Bowyer, J. F. (1999). Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine. Ann. NY Acad. Sci., 890, 495-504.
41. Cleeter, M. W., Cooper, J. M. & Schapira, A. H. (1992). Irreversible inhibition of mitochondrial complex I by 1-methyl- 4-phenylpyridinium: evidence for free radical involvement. J. Neurochem., 58, 786-9.
42. Cohen, G. & Werner, P. (1994). Free radicals, oxidative stress, and neurodegeneration. In Neurodegenerative Diseases, ed. D. B. Calne, pp. 139-161. Philadelphia:W. B. Saunders.
43. Cooper, J. M. & Clark, J. B. (1994). The structural organization of the mitochondrial respiration chain. InMitochondrialDisorders in Neurology, ed. A. H. Schapira & S. DiMauro, pp. 1-30. Boston: Butterworth-Heinemann Ltd.
44. Coyle, J. T. & Schwarcz, R. (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature, 263, 244-6.
45. Coyle, J. T. & Schwarcz, R. (1983). The use of excitatory amino acids as selective neurotoxins. In Handbook of Chemical Neuroanatomy. Method in Chemical Neuroanatomy, ed. A. Björklund & T. Hökfelt, pp. 508-27. New York: Elsevier.
46. Coyle, J. T., Molliver, M. E. & Kuhar, M. J. (1978). In situ injection of kainic acid: a new method for selectively lesioning neuronal cell bodies while sparing axons of passage. J. Comp. Neurol., 180, 301-24.
47. Cubells, J.F., Rayport, S., Rajendran, G. & Sulzer, D. (1994). Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci., 14, 2260-71.
48. Czlonkowska, A., Kohutnicka, M., Kurkowska-Jastrzebska, I. & Czlonkowski, A. (1996). Microglial reactioninMPTP(1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine) inducedParkinson's disease mice model. Neurodegeneration, 5, 137-43.
49. Dauer, W. & Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron, 39, 889-909.
50. Davey, G. P. & Clark, J. B. (1996). Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J. Neurochem., 66, 1617-24.
51. Davidson, C., Gow, A. J., Lee, T. H. & Ellinwood, E. H. (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Rev., 36, 1-22.
52. Davies, S.W. & Roberts, P. J. (1987). No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid. Nature, 327, 326-9.
53. Davis, G. C., Williams, A. C., Markey, S. P. et al. (1979). Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res., 1, 249-54.
54. Day, B. J., Patel, M., Calavetta, L., Chang, L. Y. & Stamler, J. S. (1999). A mechanism of paraquat toxicity involving nitric oxide synthase. Proc. Natl. Acad. Sci., USA, 96, 12760-5.
55. De Gori, N., Froio, F., Strongoli, M. C., De Francesco, A., Calo, M. & Nistico, G. (1988). Behavioural and electrocortical changes induced by paraquat after injection in specific areas of the brain of the rat. Neuropharmacology, 27, 201-7.
56. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J. & Schulz, J.B. (2000). Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem., 74, 2213-16.
57. Deitrich, R. & Erwin, V. (1980). Biogenic amine-aldehydecondensation products: tetrahydroisoquinolines and tryptolines (betacarbolines). Annu. Rev. Pharmacol. Toxicol., 20, 55-80.
58. Donovan, D. M., Miner, L. L., Perry, M. P. et al. (1999). Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.Mol. Brain Res., 73, 37- 49.
59. Dugan, L. L. & Choi, D. W. (1994). Excitotoxicity, free radicals, and cell membrane changes. Ann. Neurol., 35 Suppl., S17-S21.
60. Dunnett, S. B. & Iversen, S. D. (1981). Learning impairments following selective kainic acid-induced lesions within the neostriatum of rats. Behav. Brain Res., 2, 189-209.
61. Eberhardt, O., Coelln, R. V., Kugler, S. et al. (2000). Protection by synergistic effects of adenovirus-mediated X-chromosomelinked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J. Neurosci., 20, 9126-34.
62. Emerich, D. F., Zubricki, E. M., Shipley, M. T., Norman, A. B. & Sanberg, P. R. (1991). Female rats are more sensitive to the locomotor alterations following quinolinic acid-induced striatal lesions: effects of striatal transplants. Exp. Neurol., 111, 369- 78.
63. Faull, R. L. & Laverty, R. (1969). Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp. Neurol., 23, 332-40.
64. Ferger, B., Eberhardt, O., Teismann, P., de Groote, C. & Schulz, J. B. (1999). Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J. Neurochem., 73, 1329-32.
65. Fernagut, P. O., Diguet, E., Stefanova, N. et al. (2002). Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience, 114, 1005- 17.
66. Ferrante, R. J., Schulz, J. B., Kowall, N. W. & Beal, M. F. (1997). Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res., 753, 157-62.
67. Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I. & Ricaurte, G.A. (1986). Locusceruleuslesionsandeosinophilic inclusions in MPTP- treated monkeys. Ann. Neurol., 20, 449-55.
68. Forno, L. S., DeLanney, L. E., Irwin, I. & Langston, J.W. (1993). Similarities and differences between MPTP-induced parkinsonism andParkinson's disease:Neuropathologic considerations. Adv. Neurol., 60, 600-8.
69. Fumagalli, F., Gainetdinov, R. R., Valenzano, K. J. & Caron, M. G. (1998). Role of dopamine transporter in methamphetamineinduced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci., 18, 4861-9.
70. Fumagalli, F., Gainetdinov, R. R., Wang, Y.M., Valenzano, K. J., Miller, G. W. & Caron, M. G. (1999). Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci., 19, 2424-31.
71. Funata, N., Song, S. Y., Okeda, R., Funata, M. & Higashino, F. (1984). A study of experimental cyanide encephalopathy in the acute phase - physiological and neuropathological correlation. Acta Neuropathol. (Berl), 64, 99-107.
72. Gaddy, J. R., Britt, M. D., Neill, D. B. & Haigler, H. J. (1979). Susceptibility of rat neostriatum to damage by kainic acid: age dependence. Brain Res., 176, 192-6.
73. Gao, H. M., Hong, J. S., Zhang, W. & Liu, B. (2002). Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci., 22, 782-90.
74. Giovanni, A., Sieber, B.-A., Heikkila, R. E. & Sonsalla, P. K. (1994a). Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol.Exp.Ther., 270, 1000-7.
75. Giovanni, A., Sieber, B. A., Heikkila, R. E. & Sonsalla, P. K. (1991). Correlation between the neostriatal content of the 1-methyl- 4- phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther., 257, 691-7.
76. Giovanni, A., Sonsalla, P. K. & Heikkila, R. E. (1994b). Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl- 4-phenyl- 1, 2, 3, 6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther., 270, 1008-14.
77. Graham, D. G. (1978). Oxidativepathwaysfor catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol., 14, 633-43.
78. Grant, H., Lantos, P. L. & Parkinson, C. (1980). Cerebral damage in paraquat poisoning. Histopathology, 4, 185-95.
79. Greene, J. G. & Greenamyre, J.T. (1996). Manipulation ofmembrane potential modulates malonate-induced striatal excitotoxicity in vivo. J. Neurochem., 66, 637-43.
80. Greene, J. G., Porter, R. H. P., Eller, R. V. & Greenamyre, J. T. (1993). Inhibition of succinate dehydrogenase by malonic acid produces an 'excitotoxic' lesion in rat striatum. J. Neurochem., 61, 1151-4.
81. Guyot, M.C. & Hantraye, P., Dolan, R., Palfi, S., Maziere, M. & Brouillet, E. (1997). Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience, 79, 45- 56.
82. Hamre, K., Tharp, R., Poon, K., Xiong, X. & Smeyne, R. J. (1999). Differential strain susceptibility following 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res., 828, 91-103.
83. Hantraye, P., Riche, D., Maziere, M. & Isacson, O. (1990). A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudateputamen in the baboon. Exp. Neurol., 108, 91-104.
84. Hartmann, A., Troadec, J. D., Hunot, S. et al. (2001). Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci., 21, 2247-55.
85. Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y. & Minakami, S. (1990). 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun., 170, 1049-55.
86. Hatzidimitriou, G., McCann, U. D. & Ricaurte, G. A. (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci., 19, 5096-107.
87. Hefti, F., Melamed, E. & Wurtman, R. J. (1980). Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res., 195, 123-37.
88. Heikkila, R. E., Nicklas, W. J., Vyas, I. & Duvoisin, R. C. (1985). Dopaminergic toxicity of rotenone and the 1-methyl-4- phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine toxicity. Neurosci. Lett., 62, 389-94.
89. Heikkila, R. E., Sieber, B. A., Manzino, L. & Sonsalla, P. K. (1989). Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol., 10, 171-83.
90. Herve, D., Studler, J. M., Blanc, G., Glowinski, J. & Tassin, J. P. (1986). Partial protection by desmethylimipramine of the mesocortical dopamine neurones from the neurotoxic effect of 6- hydroxydopamine injected in ventral mesencephalic tegmentum. The role of noradrenergic innervation. Brain Res., 383, 47-53.
91. Higgins, D. S., Jr. & Greenamyre, J. T. (1996). [3H]dihydrorotenone binding to NADH: ubiquinone reductase (Complex I) of the electron transport chain: An autoradiographic study. J. Neurosci., 16, 3807-16.
92. Hoglinger, G. U., Feger, J., Annick, P. et al. (2003). Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem., 84, 1-12.
93. Hong, J. S., Yang, H. Y., Racagni, G. & Costa, E. (1977). Projections of substance P containing neurons from neostriatum to substantia nigra. Brain Res, 122, 541-4.
94. Hruska, R. E. & Silbergeld, E. K. (1979). Abnormallocomotion in rats after bilateral intrastriatal injection of kainic acid. Life Sci., 25, 181-93.
95. Hughes, J. T. (1988). Brain damage due to paraquat poisoning: a fatal case with neuropathological examination of the brain. Neurotoxicology, 9, 243-8.
96. Jackson-Lewis, V., Jakowec, M., Burke, R. E. & Przedborski, S. (1995). Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine. Neurodegeneration, 4, 257-69.
97. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M. & Snyder, S. H. (1985). Parkinsonism-inducing neurotoxin, N-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc. Natl Acad. Sci., USA, 82, 2173-7.
98. Javoy, F., Sotelo, C., Herbert, A. & Agid, Y. (1976). Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Res., 102, 210-15.
99. Jeon, B. S., Jackson-Lewis, V. & Burke, R. E. (1995). 6-hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration, 4, 131-7.
100. Jiang, H., Jackson-Lewis, V., Muthane, U. et al. (1993). Adenosine receptor antagonists potentiate dopamine receptor agonistinduced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res., 613, 347-51.
101. Jonsson, G. (1980). Chemical neurotoxins as denervation tools in neurobiology. Annu. Rev. Neurosci., 3, 169-87.
102. Jonsson, G. (1983). Chemical lesioning techniques: monoamine neurotoxins. In Handbook of Chemical Neuroanatomy. Vol. 1: Methods in Chemical Neuroanatomy, ed. A. Björklund & T. Hökfelt, pp. 463-507. Amsterdam: Elsevier Science Publishers B. V.
103. Jonsson, G., Fuxe, K., Hokfelt, T. & Goldstein, M. (1976). Resistance of central phenylethanolamine-n-methyl transferase containing neurons to 6-hydroxydopamine. Med. Biol., 54, 421-6.
104. Joyce, J. N., Frohna, P. A. & Neal-Beliveau, B. S. (1996). Functional andmoleculardifferentiation ofthedopaminesysteminduced by neonatal denervation. Neurosci.Biobehav.Rev., 20, 453-86.
105. Kaal, E. C., Vlug, A. S., Versleijen, M.W., Kuilman, M., Joosten, E. A. & Bar, P. R. (2000). Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. J. Neurochem., 74, 1158-65.
106. Kakhniashvili, D., Mayor, J. A., Gremse, D. A., Xu, Y. & Kaplan, R. S. (1997). Identification of a novel gene encoding the yeast mitochondrial dicarboxylate transport protein via overexpression, purification, andcharacterization of itsproteinproduct. J.Biol. Chem., 272, 4516-21.
107. Kanazawa, I., Kimura, M., Murata, M., Tanaka, Y. & Cho, F. (1990). Choreicmovementsin themacaquemonkeyinducedbykainic acid lesions of the striatum combined with L-dopa. Pharmacological, biochemical and physiological studies on neural mechanisms. Brain, 113, 509-35.
108. Kanazawa, I., Tanaka, Y. & Cho, F. (1986). 'Choreic' movement induced by unilateral kainate lesion of the striatum and LDOPA administration in monkey. Neurosci. Lett., 71, 241-6.
109. Kanthasamy, A. G., Borowitz, J. L., Pavlakovic, G. & Isom, G. E. (1994). Dopaminergic neurotoxicity of cyanide: neurochemical, histological, and behavioral characterization. Toxicol. Appl. Pharmacol., 126, 156-63.
110. Kaul, C. L. (1999). Role of sympathetic nervous system in experimental hypertension and diabetes mellitus. Clin. Exp. Hypertens., 21, 95-112.
111. Khalil, Z. & Helme, R. D. (1989). Sympathetic neurons modulate plasma extravasation in the rat through a non-adrenergic mechanism. Clin. Exp. Neurol., 26, 45-50.
112. Kilbourn, M. R., Charalambous, A., Frey, K. A., Sherman, P., Higgins, D. S., Jr. & Greenamyre, J. T. (1997). Intrastriatal neurotoxin injections reduce in vitro and in vivo binding of radiolabeled rotenoids to mitochondrial complex I. J. Cereb. Blood Flow Metab., 17, 265-72.
113. Kirik, D., Georgievska, B., Burger, C. et al. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl Acad. Sci., USA, 99, 4708-13.
114. Kita, T., Matsunari, Y., Saraya, T. et al. (2000). Methamphetamineinduced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int. J. Dev. Neurosci., 18, 521-30.
115. Klaidman, L. K., Adams, J. D., Jr., Leung, A. C., Kim, S. S. & Cadenas, E. (1993). Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic. Biol.Med., 15, 169-79.
116. Klivenyi, P., Andreassen, O. A., Ferrante, R. J. et al. (2000). Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1- methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. J. Neurosci., 20, 1-7.
117. Kohler, C. & Schwarcz, R. (1983). Comparison of ibotenate and kainate neurotoxicity in rat brain: a histological study. Neuroscience, 8, 819-35.
118. Kohutnicka, M., Lewandowska, E., Kurkowska-Jastrzebska, I., Czlonkowski, A. & Czlonkowska, A. (1998). Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Immunopharmacology, 39, 167-80.
119. Kopin, I. J. & Markey, S. P. (1988). MPTP toxicity: implication for research in Parkinson's disease. Annu. Rev. Neurosci., 11, 81- 96.
120. Kotake, Y., Yoshida, M., Ogawa, M., Tasaki, Y., Hirobe, M. & Ohta, S. (1996). Chronic administration of 1-benzyl-1, 2, 3, 4- tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci. Lett., 217, 69- 71.
121. Langston, J.W. (1987). MPTP: the promise of a new neurotoxin. In Movement Disorders 2, ed. C. D.Marsden & S. Fahn, pp. 73-90. London: Butterworths.
122. Langston, J.W. & Irwin, I. (1986). MPTP: current concepts and controversies. Clin. Neuropharmacol., 9, 485-507.
123. Langston, J.W., Ballard, P. & Irwin, I. (1983). Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-80.
124. Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A. & Karluk, D. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl- 4-phenyl- 1, 2, 3, 6-tetrahydropyridine exposure. Ann. Neurol., 46, 598-605.
125. Lapointe, N., St-Hilaire, M., Martinoli, M. G. et al. (2004). Rotenone induces non-specific central nervous systemandsystemic toxicity. FASEB J., 18, 717-19.
126. Larsen, K. E, Fon, E. A., Hastings, T. G., Edwards, R. H. & Sulzer, D. (2002). Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci., 22, 8951-60.
127. Lee, W. T., Yin, H. S. & Shen, Y. Z. (2002). The mechanisms of neuronaldeathproducedbymitochondrial toxin 3-nitropropionic acid: the roles of N-methyl-D-aspartate glutamate receptors and mitochondrial calcium overload. Neuroscience, 112, 707-16.
128. Levivier, M., Holemans, S., Togasaki, D. M., Maloteaux, J.-M., Brotchi, J. & Przedborski, S. (1994). Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol. Res., 16, 194-200.
129. Liberatore, G., Jackson-Lewis, V., Vukosavic, S. et al. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in theMPTPmodel ofParkinson's disease. Nat. Med., 5, 1403-9.
130. Liou, H. H., Chen, R. C., Tsai, Y. F., Chen, W. P., Chang, Y. C. & Tsai, M. C. (1996). Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. Toxicol. Appl. Pharmacol., 137, 34-41.
131. Liou, H. H., Tsai, M. C., Chen, C. J. et al. (1997). Environmental risk factorsandParkinson's disease:acase-controlstudyinTaiwan. Neurology, 48, 1583-8.
132. Liu, Y., Roghani, A. & Edwards, R. H. (1992). Gene transfer of a reserpine-sensitive mechanism of resistance to Nmethyl- 4-phenylpyridinium. Proc. Natl Acad. Sci., USA, 89, 9074-8.
133. Lorenc-Koci, E., Smialowska, M., Antkiewicz-Michaluk, L., Golembiowska, K., Bajkowska, M. & Wolfarth, S. (2000). Effect of acute and chronic administration of 1, 2, 3, 4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience, 95, 1049-59.
134. Lotharius, J. & O'Malley, K. L. (2000). The parkinsonisminducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem., 275, 38581-8.
135. Lotharius, J., Dugan, L. L. & O'Malley, K. L. (1999). Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci., 19, 1284-93.
136. Luthman, J., Bolioli, B., Tsutsumi, T., Verhofstad, A. & Jonsson, G. (1987). Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res. Bull., 19, 269-74.
137. Luthman, J., Fredriksson, A., Sundstrom, E., Jonsson, G. & Archer, T. (1989). Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain Res., 33, 267-77.
138. Malberg, J. E. & Seiden, L. S. (1998). Small changes in ambient temperature cause large changes in 3, 4- methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci., 18, 5086-94.
139. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L. & Di Monte, D. A. (2002). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 277, 1641-4.
140. Maragos, W. F., Jakel, R. J., Pang, Z. & Geddes, J. W. (1998). 6- Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp. Neurol., 154, 637-44.
141. Marey-Semper, I., Gelman, M. & Lévi-Strauss, M. (1995). A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment andNMDAreceptor activation. J. Neurosci., 15, 5912-18.
142. Marshall, J. F., Navarrete, R. & Joyce, J. N. (1989). Decreased striatal D1 binding density following mesotelencephalic 6- hydroxydopamine injections: an autoradiographic analysis. Brain Res., 493, 247-57.
143. Marti, M. J., James, C. J., Oo, T. F., Kelly, W. J. & Burke, R. E. (1997). Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra. J. Neurosci., 17, 2030-9.
144. Mason, S. T., Sanberg, P. R. & Fibiger, H. C. (1978). Kainic acid lesions of the striatum dissociate amphetamine and apomorphine stereotypy: similarities to Huntington's chorea. Science, 201, 352-5.
145. Massieu, L., Del Rio, P. & Montiel, T. (2001). Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience, 106, 669-77.
146. Mayer, R. A., Kindt, M. V. & Heikkila, R. E. (1986). Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine by inhibitors of 3, 4-dihydroxyphenylethylamine transport. J. Neurochem., 47, 1073-9.
147. McCormack, A. L., Thiruchelvam, M., Manning-Bog, A.B., Thiffault, C., Langston, J.W., Cory-Slechta, D. A. & DiMonte, D. A. (2002). Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis., 10, 119-27.
148. McGeer, E. G. & McGeer, P. L. (1976). Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature, 263, 517-19.
149. McGeer, E. G. & McGeer, P. L. (1978). Some factors influencing the neurotoxicity of intrastriatal injections of kainic acid. Neurochem. Res., 3, 501-17.
150. McGeer, E. G. & McGeer, P. L. (1982). Kainic acid: the neurotoxic breakthrough. Crit. Rev. Toxicol., 10, 1-26.
151. McNaught, K. S., Carrupt, P. A., Altomare, C. et al. (1998). Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol., 56, 921- 33.
152. Meldrum, A., Page, K. J., Everitt, B. J. & Dunnett, S. B. (2000). Agedependence of malonate-induced striatal toxicity. Exp. Brain Res., 134, 335-43.
153. Miller, D. B., O'Callaghan, J. P. (1994). Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther., 270, 752-60.
154. Miller, D. B., Ali, S. F., O'Callaghan, J. P. & Laws, S. C. (1998). The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. NY Acad. Sci., 844, 153-65.
155. Mizuno, Y., Sone, N. & Saitoh, T. (1987). Effects of 1-methyl- 4-phenyl- 1, 2, 3, 6-tetrahydropyridine and 1-methyl-4- phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J. Neurochem., 48, 1787-93.
156. Moratalla, R., Quinn, B., DeLanney, L. E., Irwin, I., Langston, J. W. & Graybiel, A. M. (1992). Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine. Proc. Natl Acad. Sci., USA, 89, 3859-63.
157. Moser, A., Siebecker, F., Nobbe, F. & Bohme, V. (1996). Rotational behaviour and neurochemical changes in unilateral Nmethyl- norsalsolinol and 6-hydroxydopamine lesioned rats. Exp. Brain Res., 112, 89-95.
158. Moy, S. S., Criswell, H. E. & Breese, G. R. (1997). Differential effects of bilateral dopamine depletion in neonatal and adult rats. Neurosci. Biobehav. Rev., 21, 425-35.
159. Moy, L. Y., Zeevalk, G.D. & Sonsalla, P. K. (2000). Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem., 74, 1656-65.
160. Muthane, U., Ramsay, K. A., Jiang, H. et al. (1994). Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine in C57/bl and CD-1mice. Exp.Neurol., 126, 195-204.
161. Nagatsu, T. (1997). Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci. Res., 29, 99-111.
162. Nagatsu, T. & Yoshida, M. (1988). An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci. Lett., 87, 178- 82.
163. Naoi, M., Maruyama, W., Dostert, P. et al. (1996). Dopaminederived endogenous 1(R), 2(N)-dimethyl-6, 7-dihydroxy- 1, 2, 3, 4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res., 709, 285-95.
164. Nicklas, W. J., Vyas, I. & Heikkila, R. E. (1985). Inhibition of NADHlinked oxidation in brain mitochondria byMPP+, a metabolite of the neurotoxin MPTP. Life Sci., 36, 2503-8.
165. O'Callaghan, J. P., Miller, D. B. & Reinhard, J. F. (1990). Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine. Brain Res., 521, 73-80.
166. Offen, D., Beart, P. M., Cheung, N. S. et al. (1998). Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci., USA, 95, 5789-94.
167. Okun, J. G., Lummen, P. & Brandt, U. (1999). Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH: ubiquinone oxidoreductase). J.Biol. Chem., 274, 2625-30.
168. Olney, J.W., Ho, O. L. & Rhee, V. (1971). Cytotoxic effects of acidicand sulphur containing amino acids on the infant mouse central nervous system. Exp. Brain Res., 14, 61-76.
169. Ouary, S., Bizat, N., Altairac, S. et al. (2000). Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience, 97, 521- 30.
170. Pajor, A. M., Gangula, R. & Yao, X. (2001). Cloning and functional characterization of a high-affinity Na(+)/dicarboxylate cotransporter from mouse brain. Am. J. Physiol. Cell Physiol., 280, C1215-23.
171. Pennathur, S., Jackson-Lewis, V., Przedborski, S. & Heinecke, J. W. (1999). Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o, o
172. Perier, C., Bove, J., Vila, M. & Przedborski, S. (2003). The rotenone model of Parkinson's disease. Trends Neurosci., 26, 345-6.
173. Perry, T. L., Jones, K. & Hansen, S. (1988). Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice. Neurosci. Lett., 85, 101-4.
174. Petzinger, G. M. & Langston, J.W. (1998). The MPTP-lesioned nonhuman primate: a model for Parkinson's disease. In Advances inNeurodegenerativeDisorders.Parkinson'sDisease, ed. J.Marwah, H. Teiltelbaum, pp. 113-48. Scottsdale: Prominent Press.
175. Portera-Cailliau, C., Price, D. L. & Martin, L. J. (1997a). Excitotoxic neuronaldeathintheimmaturebrain isanapoptosis-necrosis morphological continuum. J. Comp. Neurol., 378, 70-87.
176. Portera-Cailliau, C., Price, D. L. & Martin, L. J. (1997b). Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J. Comp. Neurol., 378, 88- 104.
177. Przedborski, S. & Dawson, T. M. (2001). The role of nitric oxide in Parkinson's disease. In Parkinson's Disease. Methods and Protocols, ed. M. M.Mouradian, pp. 113-36. New Jersey: Humana Press.
178. Przedborski, S. & Vila, M. (2003). The 1-methyl-4-phenyl 1-1, 2, 3, 6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci., 991, 189-98.
179. Przedborski, S., Jackson-Lewis, V., Popilskis, S. et al. (1991). Unilateral MPTP-induced parkinsonism in monkeys: a quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgie, 37, 377-82.
180. Przedborski, S., Kostic, V., Jackson-Lewis, V. et al. (1992). Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridineinduced neurotoxicity. J. Neurosci., 12, 1658-67.
181. Przedborski, S., Levivier, M., Jiang, H. et al. (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience, 67, 631-47.
182. Przedborski, S., Jackson-Lewis, V., Yokoyama, R., Shibata, T., Dawson, V. L. & Dawson, T. M. (1996). Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine)- induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci., USA, 93, 4565-71.
183. Przedborski, S., Jackson-Lewis, V., Djaldetti, R. et al. (2000). The parkinsonian toxin MPTP: action and mechanism. RestorNeurol. Neurosci, 16, 135-42.
184. Przedborski, S., Chen, Q., Vila, M. et al. (2001a). Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem., 76, 637-40.
185. Przedborski, S., Jackson-Lewis, V., Naini, A. et al. (2001b). The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem., 76, 1265-74.
186. Przedborski, S. & Vila, M. (2001). MPTP: A review of its mechanisms of neurotoxicity. Clin. Neurosci. Res., 1, 407-18.
187. Przedborski, S., Vila, M. & Jackson-Lewis, V. (2003). Series Introduction: Neurodegeneration: What is it and where are we? J. Clin. Invest., 111, 3-10.
188. Ramsay, R. R. & Singer, T. P. (1986). Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, by mitochondria. J. Biol. Chem., 261, 7585-7.
189. Ramsay, R. R., Krueger, M. J., Youngster, S. K., Gluck, M. R., Casida, J. E. & Singer, T. P. (1991). Interaction of 1-methyl- 4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem., 56, 1184-90.
190. Reynolds, D. S., Carter, R. J. & Morton, A. J. (1998). Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci., 18, 10116-27.
191. Ricaurte, G. A., Sabol, K. E. & Seiden, L. S. (1994). Functional consequences of neurotoxic amphetamine exposure. In Amphetamine and its Analogs. Psychopharmacology, Toxicology, and Abuse, ed. A. K. Cho & D. S. Segal, pp. 297-313. New York: Academic Press.
192. Rodriguez, D. M., Abdala, P., Barroso-Chinea, P., Obeso, J. & Gonzalez-Hernandez, T. (2001). Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav.Brain Res., 122, 79-92.
193. Rossetti, Z. L., Sotgiu, A., Sharp, D. E., Hadjiconstantinou, M. & Neff, M. (1988). 1-Methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol., 37, 4573-4.
194. Sanberg, P. R., Pisa, M. & McGeer, E. G. (1979). Strain differences and kainic acid neurotoxicity. Brain Res., 166, 431-5.
195. Sanberg, P. R., Calderon, S. F., Giordano, M., Tew, J. M. & Norman, A. B. (1989). The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp. Neurol., 105, 45-53.
196. Sanchez-Ramos, J. R. (1993). Toxin-induced parkinsonism. In ParkinsonianSyndromes, ed.M.B.Stern& W. C.Koller, pp.155- 71. New York:Marcel Dekker, Inc.
197. Saner, A. & Thoenen, H. (1971). Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol. Pharmacol., 7, 147-54.
198. Saporito, M.S., Brown, E. M., Miller, M.S. & Carswell, S. (1999). CEP- 1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridinemediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther., 288, 421-7.
199. Saporito, M. S., Thomas, B. A. & Scott, R.W. (2000). MPTP activates c-JunNH(2)-terminalkinase (JNK)andits upstreamregulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem., 75, 1200-8.
200. Sauer, H. & Oertel, W. H. (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 59, 401-15.
201. Schneider, J. S. & Roeltgen, D. P. (1993). Delayed matching-tosample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res., 615, 351-4.
202. Schneider, J. S., Tinker, J. P., Van Velson, M., Menzaghi, F. & Lloyd, G. K. (1999). Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic lowdose MPTP-treated monkeys. J. Pharmacol. Exp. Ther., 290, 731-9.
203. Schuler, F. & Casida, J. E. (2001). Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreductase established by photoaffinity labeling. Biochim. Biophys. Acta, 1506, 79-87.
204. Schulz, J. B., Matthews, R. T., Jenkins, B. G., Brar, P. & Beal, M. F. (1995a). Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J. Cereb. Blood Flow Metab., 15, 948-52.
205. Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E. & Beal, M. F. (1995b). Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem., 64, 936-9.
206. Schulz, J. B., Henshaw, D. R., MacGarvey, U. & Beal, M. F. (1996). Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochem. Int., 29, 167-71.
207. Schulz, J. B., Weller, M., Matthews, R. T. et al. (1998). Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ., 5, 847-57.
208. Schwarcz, R. & Coyle, J. T. (1977). Striatal lesions with kainic acid: neurochemical characteristics. Brain Res., 127, 235-49.
209. Schwarcz, R., Scholz, D. & Coyle, J. T. (1978). Structure-activity relations for the neurotoxicity of kainic acid derivatives and glutamate analogues. Neuropharmacology, 17, 145-51.
210. Schwarcz, R., Hokfelt, T., Fuxe, K., Jonsson, G., Goldstein, M. & Terenius, L. (1979). Ibotenic acid-induced neuronal degeneration a morphological and neurochemical study. Exp. Brain Res., 37, 199-216.
211. Scorza, M. C., Carrau, C., Silveira, R., Zapata-Torres, G., Cassels, B. K. & Reyes-Parada, M.(1997). Monoamineoxidaseinhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem. Pharmacol., 54, 1361-9.
212. Segal, D. S. & Kuczenski, R. (1994). Behavioral pharmacology of amphetamine. In Amphetamine and its Analogs. Psychopharmacology, Toxicology, and Abuse, ed. A. K. Cho & D. S. Segal, pp. 115-50. New York: Academic Press.
213. Seniuk, N. A., Tatton, W. G. & Greenwood, C. E. (1990). Dosedependent destruction of the coeruleus-cortical and nigralstriatal projections by MPTP. Brain Res., 527, 7-20.
214. Sherman, B. E. & Chole, R. A. (2000). Sympathectomy, which inducesmembranousboneremodeling, hasnoeffectonendochondral long bone remodeling in vivo. J. Bone.Miner. Res., 15, 1354-60.
215. Shimizu, K., Ohtaki, K., Matsubara, K. et al. (2001). Carriermediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res., 906, 135-42.
216. Smith, J. G. (1988). Paraquat poisoning by skin absorption: a review. Hum. Toxicol., 7, 15-19.
217. Snow, B. J., Vingerhoets, F. J., Langston, J.W., Tetrud, J.W., Sossi, V. & Calne, D. B. (2000). Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry, 68, 313-16.
218. Sonsalla, P. K. & Heikkila, R. E. (1986). The influence of dose and dosing intervalonMPTP-induceddopaminergicneurotoxicity in mice. Eur. J. Pharmacol., 129, 339-45.
219. Sonsalla, P. K., Jochnowitz, N. D., Zeevalk, G. D., Oostveen, J. A. & Hall, E. D. (1996). Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res., 738, 172- 5.
220. Sonsalla, P. K., Manzino, L., Sinton, C. M., Liang, C. L., German, D. C. & Zeevalk, G.D. (1997). Inhibitionof striatalenergymetabolism produces cell loss in the ipsilateral substantia nigra. BrainRes., 773, 223-6.
221. Staal, R. G. & Sonsalla, P. K. (2000). Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4- phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther., 293, 336-42.
222. Staal, R. G., Hogan, K. A., Liang, C. L., German, D. C. & Sonsalla, P. K. (2000). In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther., 293, 329-35.
223. Storey, E., Hyman, B. T., Jenkins, B. et al. (1992). 1-Methyl-4- phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem., 58, 1975-8.
224. Sulzer, D., Maidment, N. T. & Rayport, S. (1993). Amphetamine and otherweakbasesact topromotereverse transport ofdopamine in ventral midbrain neurons. J. Neurochem., 60, 527- 35.
225. Sulzer, D., Chen, T.-K., Lau, Y.Y., Kristensen, H., Rayport, S. & Ewing, A. (1995). Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci., 15, 4102-8.
226. Sun, Z., Xie, J. & Reiner, A. (2002). The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp. Neurol., 176, 55-65.
227. Takahashi, N., Miner, L. L., Sora, I. et al. (1997). VMAT2 knockout mice: heterozygotes display reduced amphetamineconditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci., USA, 94, 9938-43.
228. Talpade, D. J., Greene, J. G., Higgins, D. S., Jr. & Greenamyre, J. T. (2000). In vivo labeling of mitochondrial complex I (NADH: ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J. Neurochem., 75, 2611-21.
229. Tatton, N. A. & Kish, S. J. (1997). In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience, 77, 1037-48.
230. Teismann, P., Tieu, K., Choi, D. K. et al. (2003). Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci., USA, 100, 5473-8.
231. Tetrud, J.W., Langston, J.W., Redmond, D. E., Jr., Roth, R. H., Sladek, J. R. & Angel, R.W. (1986). MPTP-inducedtremorinhumanand non-human primates. Neurology, 36 (suppl 1), 308.
232. Thiffault, C., Langston, J. W. & Di Monte, D. A. (2000). Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res., 885, 283-8.
233. Thiruchelvam, M., Brockel, B. J., Richfield, E. K., Baggs, R. B. & Cory-Slechta, D. A. (2000a). Potentiatedandpreferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res., 873, 225-34.
234. Thiruchelvam, M., Richfield, E. K., Baggs, R. B., Tank, A.W. & Cory-Slechta, D. A. (2000b). The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci., 20, 9207-14.
235. Thiruchelvam, M., McCormack, A., Richfield, E. K. et al. (2003). Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci., 18, 589- 600.
236. Tieu, K., Ischiropoulos, H. & Przedborski, S. (2003). Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life, 55, 329-35.
237. Trimmer, P. A., Smith, T. S., Jung, A. B. & Bennett, J. P., Jr. (1996). Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration, 5, 233-9.
238. Trulson, M.E., Cannon, M.S., Faegg, T. S. & Raese, J.D. (1985). Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res. Bull., 15, 569-77.
239. Ungerstedt, U. (1968). 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5, 107-10.
240. Ungerstedt, U. (1971a). Adipsia and aphagia after 6-hydroxydopamine induced degenerationofthenigro-striataldopaminesystem. ActaPhysiol. Scand. Suppl, 367, 95-122.
241. Ungerstedt, U. (1971b). Postsynaptique supersensitivity after 6- hydroxydopamine induced degeneration of the nigro-striatal system in the rat brain. Acta Physiol. Scand., Suppl.367, 69-93.
242. Ungerstedt, U. (1971c). Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand., Suppl. 367, 1-48.
243. Ungerstedt, U. & Arbuthnott, G. (1970). Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res., 24, 485-93.
244. Vila, M., Jackson-Lewis, V., Vukosavic, S. et al. (2001a). Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl Acad. Sci., USA, 98, 2837-42.
245. Vila, M., Jackson Lewis, V., Guégan, C. et al. (2001b). The role of glial cells in Parkinson's disease. Curr. Opin. Neurol., 14, 483-9.
246. Vingerhoets, F. J., Snow, B. J., Tetrud, J.W., Langston, J.W., Schulzer, M. & Calne, D. B. (1994). Positron emission tomographic evidenceforprogression ofhumanMPTP-induceddopaminergic lesions. Ann. Neurol., 36, 765-70.
247. Widdowson, P. S., Farnworth, M. J., Simpson, M. G. & Lock, E. A. (1996a). Influence of age on the passage of paraquat through the blood-brain barrier in rats: a distribution and pathological examination. Hum. Exp. Toxicol., 15, 231-6.
248. Widdowson, P. S., Farnworth, M. J., Upton, R. & Simpson, M. G. (1996b). No changes in behaviour, nigro-striatal system neurochemistry or neuronal cell death following toxic multiple oral paraquat administration to rats. Hum. Exp. Toxicol., 15, 583-91.
249. Wu, D. C., Jackson-Lewis, V., Vila, M. et al. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22, 1763-71.
250. Wu, D. C., Teismann, P., Tieu, K. et al. (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine model of Parkinson's disease. Proc. Natl Acad. Sci., USA, 100, 6145-50.
251. Wullner, U., Young, A. B., Penney, J. B. & Beal, M. F. (1994). 3- Nitropropionic acid toxicity in the striatum. J.Neurochem., 63, 1772-81.
252. Xia, X. G., Schmidt, N., Teismann, P., Ferger, B. & Schulz, J. B. (2001). Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. J. Neurochem., 79, 63- 70.
253. Yang, L., Matthews, R. T., Schulz, J. B. et al. (1998). 1-Methyl-4- phenyl-1, 2, 3, 6-tetrahydropyrideneurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci., 18, 8145-52.
254. Yoshida, M., Niwa, T. & Nagatsu, T. (1990). Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci. Lett., 119, 109-13.
255. Yoshida, M., Ogawa, M., Suzuki, K. & Nagatsu, T. (1993). Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Adv. Neurol., 60, 207-11.
256. Yuan, J., Callahan, B. T., McCann, U.D. & Ricaurte, G. A. (2001). Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J. Neurochem., 77, 1338-47.
257. Yuan, J., Cord, B. J., McCann, U. D., Callahan, B. T. & Ricaurte, G. A. (2002). Effect of depleting vesicularandcytoplasmicdopamine on methylenedioxymethamphetamine neurotoxicity. J. Neurochem., 80, 960-9.
258. Zaczek, R., Nelson, M. F. & Coyle, J. T. (1978). Effects of anaesthetics and anticonvulsants on the action of kainic acid in the rat hippocampus. Eur. J. Pharmacol., 52, 323-7.
259. Zaczek, R., Simonton, S. & Coyle, J. T. (1980). Local and distant neuronal degeneration following intrastriatal injection of kainic acid. J. Neuropathol. Exp. Neurol., 39, 245-64.
260. Zaczek, R., Culp, S. & De Souza, E. B. (1991a). Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J. Pharmacol. Exp. Ther., 257, 830-5.
261. Zaczek, R., Culp, S., Goldberg, H., Mccann, D. J. & De Souza, E. B. (1991b). Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J. Pharmacol. Exp. Ther., 257, 820-9.
262. Zeevalk, G.D., Derr-Yellin, E. & Nicklas, W. J. (1995). NMDAreceptor involvementin toxicity todopamineneuronsin vitrocausedby the succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem., 64, 455-8.
263. Zeevalk, G. D., Manzino, L., Hoppe, J. & Sonsalla, P. (1997). In vivo vulnerability of dopamine neurons to inhibition of energy metabolism. Eur. J. Pharmacol., 320, 111-19.
264. Zigmond, M. J., Abercrombie, E. D., Berger, T. W., Grace, A. A. & Stricker, E. M. (1990). Compensations after lesions of the central dopaminergic neurons: some clinical and basic implications. Trends Neurosci., 13, 290-6.
265. Zubrycki, E. M., Emerich, D. F. & Sanberg, P. R. (1990). Sex differences in regulatory changes following quinolinic acid-induced striatal lesions. Brain Res. Bull., 25, 633-7.